 |
인쇄하기
취소
|
Kanarb likely to be prescribed in 40 general hospitals in second half
Boryung Pharmaceutical is enjoying brisk sales of its new antihypertensive drug, Kanarb (fimasartan).
Monthly sales of Kanarb is expected to reach 1,000 million won in the first half of this year, as it has succeeded to land in 40 general hospitals and 6,800 clinics nationwide since its release in March.
Kanarb is Korea’s 15th new medicine developed by a local drug manufacturer.
Since ...
Monthly sales of Kanarb is expected to reach 1,000 million won in the first half of this year, as it has succeeded to land in 40 general hospitals and 6,800 clinics nationwide since its release in March.
Kanarb is Korea’s 15th new medicine developed by a local drug manufacturer.
Since ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.